Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Convertible Debt (2016 - 2020)

Amicus Therapeutics (FOLD) has disclosed Convertible Debt for 5 consecutive years, with $2.2 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Convertible Debt rose 6.43% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Jun 2020, up 6.43%, and an annual FY2019 reading of $2.1 million, down 98.78% over the prior year.
  • Convertible Debt was $2.2 million for Q2 2020 at Amicus Therapeutics, up from $2.2 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $175.0 million in Q4 2018 and bottomed at $2.1 million in Q2 2019.
  • Average Convertible Debt over 5 years is $100.8 million, with a median of $156.9 million recorded in 2017.
  • The sharpest move saw Convertible Debt rose 6.6% in 2018, then tumbled 98.78% in 2019.
  • Year by year, Convertible Debt stood at $154.5 million in 2016, then grew by 6.28% to $164.2 million in 2017, then increased by 6.6% to $175.0 million in 2018, then plummeted by 98.78% to $2.1 million in 2019, then increased by 3.38% to $2.2 million in 2020.
  • Business Quant data shows Convertible Debt for FOLD at $2.2 million in Q2 2020, $2.2 million in Q1 2020, and $2.1 million in Q4 2019.